GLP1R and irritable bowel syndrome: In IBS, where mucosal immune alterations can contribute to symptom generation, targeting such GPCR pathways (for example, enhancing FFAR2 signaling with SCFAs or modulating GLP-1R) may restore immune homeostasis.